NSE: DIVISLAB | BSE: 532488

Expensive Performer

Download real time

6131.50 -0.50 (-0.01%)

285.3K NSE+BSE Volume

NSE 29 Aug, 2025 3:50 PM (IST)

162,772.1

Market Cap

Market Runner Up

0.7

Beta 1Year

Very Low volatility

Analyst Downgrade

Deven Choksey downgrades Divi's Labs to a 'Hold' call, expects a revenue CAGR of 16.1% over FY26-27 See details

Divi's Laboratories Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for DIVISLAB, BSE:532488 Divi's Laboratories Ltd.

Divi's Laboratories Ltd.

29 May 2017

6131.50

-0.01%

Divis Laboratories Ltd Q4FY17 results comment

Results Update: Divi's Laboratories Ltd.

HDFC Securities

Revenue increased by 9.21% to Rs. 1063.14 Cr in Q4FY17 when compared to the previous quarter.

Divi's Laboratories Ltd. is trading below its 30 day SMA of 6355.8

Divi's Laboratories Ltd.

29 May 2017, 09:39AM

6131.50

-0.01%

Divis Laboratories (4QFY17): Subdued quarter. Maintain BUY

Buy: Divi's Laboratories Ltd.

Target

HDFC Securities

Post the import alert (IA) on its crucial Unit II plant, Divis Labs (DIVI) reported mixed 4QFY17 numbers. The top-line declined 3% YoY, and the EBITDA margin came in at ~34% (vs ~36% in 4QFY16).

Divi's Laboratories Ltd. is trading below its 30 day SMA of 6355.8

Divi's Laboratories Ltd.

29 May 2017, 12:00AM

6131.50

-0.01%

Divi's Laboratories

Hold: Divi's Laboratories Ltd.

Target

ICICI Securities Limited

ICICI Securities Ltd | Retail Equity Research Revenues fell 3% YoY to | 1067 crore against I-direct estimate of | 1041 crore. Both generic CS segments registered de-growth of 1%, 3%, respectively, due to impact of capacity constraints & import alert EBITDA margins declined 224 bps to 33.9% (I-direct estimate: 36.8%) mainly due to increase in other expenditure, which included forex...

Divi's Laboratories Ltd. is trading above its 200 day SMA of 6111.2

Divi's Laboratories Ltd.

10 Apr 2017

6131.50

-0.01%

Company Update:Divis Lab.

Hold: Divi's Laboratories Ltd.

Target

Axis Direct

Divi's management, in its conference call post import alert on Unit 2, highlighted the alert will impact only ~5% of its total sales, as remaining 17% of sales in US is under exemption list. Company did not share any timelines for remediation (as awaiting detailed comments by USFDA)

Deven Choksey released a Accumulate report for Divi's Laboratories Ltd. with a price target of 6499.0 on 29 Aug, 2025.

Divi's Laboratories Ltd.

21 Mar 2017

6131.50

-0.01%

Divis Laboratories (Update): Bottomed out? Maintain BUY

Buy: Divi's Laboratories Ltd.

HDFC Securities

The US FDA has finally put an end to speculation about the outcome of its Dec-16 inspection of Divis Labs (DIVI) Unit 2 facility in Vizag by issuing an import alert (IA). However, the US FDA has also exempted 10 key products in which DIVI has a significant market share in the US.

Divi's Laboratories .. has an average target of 6414.33 from 6 brokers.

Divi's Laboratories Ltd.

21 Mar 2017

6131.50

-0.01%

Divi's Laboratories

Hold: Divi's Laboratories Ltd.

Recommendation Target

ICICI Securities Limited

Immediate impact nominal but suspense over future revenues The management has indicated just 3-4% impact due to exemption of key products from the import alert. The impact also includes effect of CRAMS business, which has a direct link with DMFs from Vizag. However, we are more concerned about the spill over effect of import alert on the custom synthesis business, which is driven by customer stickiness. This may also trigger other regulatory inspections especially by European authority EMA. EU, US together contributed ~73% of total sales in FY16. Note that...

Divi's Laboratories .. has an average target of 6414.33 from 6 brokers.

Divi's Laboratories Ltd.

10 Feb 2017

6131.50

-0.01%

Result Update:Divis Lab.

Hold: Divi's Laboratories Ltd.

Axis Direct

While Q3 EBITDA was inline with estimate, PAT of Rs 2.68bn was 10% below our estimate due to higher taxes. Revenue growth was muted at 13% YoY (9M was 14% YoY, 10% in cc terms). Divi'sguided for 10- 15% cc revenue growth for FY17/18 vs.15% earlier, given delay in adding capacities (Vizagand Kakina..

Divi's Laboratories Ltd. is trading below its 30 day SMA of 6355.8

Is Divi's Laboratories Ltd. worth buying?

750 Votes:

Buy 78.0%

Sell 15.07%

Hold 6.93%

RESEARCH REPORTS

Accumulate SEE REPORTS >

pdf

Accumulate SEE REPORTS >

pdf